Form 4: Lenz Therapeutics Director Acquires 27,000 Stock Options
SEC Form 4 Filing
Director Jeffrey P. George acquired 27,000 stock options in Lenz Therapeutics, Inc. on March 21, 2024.
Summary
- On March 21, 2024, Jeffrey P. George, a director of Lenz Therapeutics, Inc., acquired 27,000 stock options.
- The exercise price of these options is $15.05.
- The options vest monthly over three years, starting from March 21, 2024, contingent upon continued service as a Service Provider as defined in the Issuer's 2024 Equity Incentive Plan.
- The options expire on March 20, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows the public to see if those with inside knowledge of a company are buying or selling stock.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/21/2024 | Date of transaction: Jeffrey P. George acquired 27,000 stock options; Vesting Commencement Date |
| 03/20/2034 | Expiration date of the stock options |
| 03/25/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.